CCL26 and pulmonary fibrosis: Several recent publications have shown grounds for promise in identifying additional blood and tissue biomarkers, such as IL-1β, CXCL10, Eotaxin-3, PARC and IgE, in both COPD [25,39,41,162] and pulmonary fibrosis [53,61,163].